Agronomic performance of 21 new disease resistant winegrape varieties grown in northeast Italy

The goal of the field trial was to evaluate the agronomic performance of 21 (10 red and 11 white) winegrape varieties obtained from recent breeding programmes for disease resistance developed in Hungary, Germany, and Italy. The tested red varieties were as follows: ‘Cabernet Carbon’, ‘Cabernet Eidos’, ‘Cabernet Volos’, ‘Julius’, ‘Merlot Khorus’, ‘Merlot Kanthus’, ‘Monarch’, ‘Prior’, UD. 31.103, ‘Vinera’. The tested white varieties were as follows: ‘Aromera’, ‘Bronner’, ‘Fleurtai’, ‘Johanniter’, ‘Muscaris’, ‘Souvignier Gris’, ‘Sauvignon Kretos’, ‘Sauvignon Nepis’, ‘Sauvignon Rytos’, ‘Solaris’, ‘Soreli’. ‘Merlot’ (red) and ‘Glera’ (white) were included as control. The experimental vineyard was established in Castelfranco Veneto on the plain, in 2014. Spray treatments were applied against downy and powdery mildew, by using only copper and sulphur. Grape production, grape quality, and phenology were recorded over a six-year-period, while disease resistance (downy mildew, powdery mildew, black rot and anthracnose) was detected only during a few years. The most significant findings were: a) all varieties showed a good level of downy mildew resistance, especially ‘Cabernet Carbon’, ‘Monarch’, ‘Prior’, UD 31.103, ‘Muscaris’, ‘Solaris’, ‘Souvignier Gris’, ‘Bronner’, ‘Fleurtai’, ‘Aromera’; b) no powdery mildew attacks were detected in any variety; c) ‘Monarch’, ‘Muscaris’, ‘Solaris’ and ‘Souvignier Gris’ also showed a high level of resistance towards black rot and anthracnose; d) red grape varieties had an earlier bud burst as compared to ‘Merlot’, and, concerning ripening, some varieties were earlier than ‘Merlot’, other ones were later; e) white varieties had a later bud burst but an earlier ripening time as compared to ‘Glera’; f) grape production and quality changed significantly depending on the varieties, being titratable acidity higher than 6.4 g L-1 tartaric acid and pH lower than 3.5; also the year affected in a significant way those parameters as well as the interaction between the genotype and the year. In conclusion, the tested varieties behaved positively in terms of environmental sustainability

Beta-Blocker Use in Older Hospitalized Patients Affected by Heart Failure and Chronic Obstructive Pulmonary Disease: An Italian Survey From the REPOSI Register

Beta (β)-blockers (BB) are useful in reducing morbidity and mortality in patients with heart failure (HF) and concomitant chronic obstructive pulmonary disease (COPD). Nevertheless, the use of BBs could induce bronchoconstriction due to β2-blockade. For this reason, both the ESC and GOLD guidelines strongly suggest the use of selective β1-BB in patients with HF and COPD. However, low adherence to guidelines was observed in multiple clinical settings. The aim of the study was to investigate the BBs use in older patients affected by HF and COPD, recorded in the REPOSI register. Of 942 patients affected by HF, 47.1% were treated with BBs. The use of BBs was significantly lower in patients with HF and COPD than in patients affected by HF alone, both at admission and at discharge (admission, 36.9% vs. 51.3%; discharge, 38.0% vs. 51.7%). In addition, no further BB users were found at discharge. The probability to being treated with a BB was significantly lower in patients with HF also affected by COPD (adj. OR, 95% CI: 0.50, 0.37-0.67), while the diagnosis of COPD was not associated with the choice of selective β1-BB (adj. OR, 95% CI: 1.33, 0.76-2.34). Despite clear recommendations by clinical guidelines, a significant underuse of BBs was also observed after hospital discharge. In COPD affected patients, physicians unreasonably reject BBs use, rather than choosing a β1-BB. The expected improvement of the BB prescriptions after hospitalization was not observed. A multidisciplinary approach among hospital physicians, general practitioners, and pharmacologists should be carried out for better drug management and adherence to guideline recommendations

The “Diabetes Comorbidome”: A Different Way for Health Professionals to Approach the Comorbidity Burden of Diabetes

(1) Background: The disease burden related to diabetes is increasing greatly, particularly in older subjects. A more comprehensive approach towards the assessment and management of diabetes’ comorbidities is necessary. The aim of this study was to implement our previous data identifying and representing the prevalence of the comorbidities, their association with mortality, and the strength of their relationship in hospitalized elderly patients with diabetes, developing, at the same time, a new graphic representation model of the comorbidome called “Diabetes Comorbidome”. (2) Methods: Data were collected from the RePoSi register. Comorbidities, socio-demographic data, severity and comorbidity indexes (Cumulative Illness rating Scale CIRS-SI and CIRS-CI), and functional status (Barthel Index), were recorded. Mortality rates were assessed in hospital and 3 and 12 months after discharge. (3) Results: Of the 4714 hospitalized elderly patients, 1378 had diabetes. The comorbidities distribution showed that arterial hypertension (57.1%), ischemic heart disease (31.4%), chronic renal failure (28.8%), atrial fibrillation (25.6%), and COPD (22.7%), were the more frequent in subjects with diabetes. The graphic comorbidome showed that the strongest predictors of death at in hospital and at the 3-month follow-up were dementia and cancer. At the 1-year follow-up, cancer was the first comorbidity independently associated with mortality. (4) Conclusions: The “Diabetes Comorbidome” represents the perfect instrument for determining the prevalence of comorbidities and the strength of their relationship with risk of death, as well as the need for an effective treatment for improving clinical outcomes

Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both

Background and objective: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) mutually increase the risk of being present in the same patient, especially if older. Whether or not this coexistence may be associated with a worse prognosis is debated. Therefore, employing data derived from the REPOSI register, we evaluated the clinical features and outcomes in a population of elderly patients admitted to internal medicine wards and having COPD, HF or COPD + HF. Methods: We measured socio-demographic and anthropometric characteristics, severity and prevalence of comorbidities, clinical and laboratory features during hospitalization, mood disorders, functional independence, drug prescriptions and discharge destination. The primary study outcome was the risk of death. Results: We considered 2,343 elderly hospitalized patients (median age 81 years), of whom 1,154 (49%) had COPD, 813 (35%) HF, and 376 (16%) COPD + HF. Patients with COPD + HF had different characteristics than those with COPD or HF, such as a higher prevalence of previous hospitalizations, comorbidities (especially chronic kidney disease), higher respiratory rate at admission and number of prescribed drugs. Patients with COPD + HF (hazard ratio HR 1.74, 95% confidence intervals CI 1.16-2.61) and patients with dementia (HR 1.75, 95% CI 1.06-2.90) had a higher risk of death at one year. The Kaplan-Meier curves showed a higher mortality risk in the group of patients with COPD + HF for all causes (p = 0.010), respiratory causes (p = 0.006), cardiovascular causes (p = 0.046) and respiratory plus cardiovascular causes (p = 0.009). Conclusion: In this real-life cohort of hospitalized elderly patients, the coexistence of COPD and HF significantly worsened prognosis at one year. This finding may help to better define the care needs of this population

Antidiabetic Drug Prescription Pattern in Hospitalized Older Patients with Diabetes

Objective: To describe the prescription pattern of antidiabetic and cardiovascular drugs in a cohort of hospitalized older patients with diabetes. Methods: Patients with diabetes aged 65 years or older hospitalized in internal medicine and/or geriatric wards throughout Italy and enrolled in the REPOSI (REgistro POliterapuie SIMI—Società Italiana di Medicina Interna) registry from 2010 to 2019 and discharged alive were included. Results: Among 1703 patients with diabetes, 1433 (84.2%) were on treatment with at least one antidiabetic drug at hospital admission, mainly prescribed as monotherapy with insulin (28.3%) or metformin (19.2%). The proportion of treated patients decreased at discharge (N = 1309, 76.9%), with a significant reduction over time. Among those prescribed, the proportion of those with insulin alone increased over time (p = 0.0066), while the proportion of those prescribed sulfonylureas decreased (p < 0.0001). Among patients receiving antidiabetic therapy at discharge, 1063 (81.2%) were also prescribed cardiovascular drugs, mainly with an antihypertensive drug alone or in combination (N = 777, 73.1%). Conclusion: The management of older patients with diabetes in a hospital setting is often sub-optimal, as shown by the increasing trend in insulin at discharge, even if an overall improvement has been highlighted by the prevalent decrease in sulfonylureas prescription

Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both

Background and objective: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) mutually increase the risk of being present in the same patient, especially if older. Whether or not this coexistence may be associated with a worse prognosis is debated. Therefore, employing data derived from the REPOSI register, we evaluated the clinical features and outcomes in a population of elderly patients admitted to internal medicine wards and having COPD, HF or COPD + HF. Methods: We measured socio-demographic and anthropometric characteristics, severity and prevalence of comorbidities, clinical and laboratory features during hospitalization, mood disorders, functional independence, drug prescriptions and discharge destination. The primary study outcome was the risk of death. Results: We considered 2,343 elderly hospitalized patients (median age 81 years), of whom 1,154 (49%) had COPD, 813 (35%) HF, and 376 (16%) COPD + HF. Patients with COPD + HF had different characteristics than those with COPD or HF, such as a higher prevalence of previous hospitalizations, comorbidities (especially chronic kidney disease), higher respiratory rate at admission and number of prescribed drugs. Patients with COPD + HF (hazard ratio HR 1.74, 95% confidence intervals CI 1.16-2.61) and patients with dementia (HR 1.75, 95% CI 1.06-2.90) had a higher risk of death at one year. The Kaplan-Meier curves showed a higher mortality risk in the group of patients with COPD + HF for all causes (p = 0.010), respiratory causes (p = 0.006), cardiovascular causes (p = 0.046) and respiratory plus cardiovascular causes (p = 0.009). Conclusion: In this real-life cohort of hospitalized elderly patients, the coexistence of COPD and HF significantly worsened prognosis at one year. This finding may help to better define the care needs of this population

"Valutazione dei risultati dell'impianto di stent coronarici riassorbibili mediante tomografia intravascolare a coerenza ottica"

Premessa - Lo scaffold riassorbibile ABSORB è stato utilizzato per la prima volta nell’uomo nel 2007. Ad oggi sono stati pubblicati numerosissimi studi clinici su questo dispositivo, ma solo recentemente sono stati resi pubblici i risultati ad 1 anno del primo studio randomizzato di confronto tra l’ABSORB e lo stent medicato metallico di riferimento, che hanno mostrato una sicurezza ed un’efficacia sovrapponibile. I risultati di questo trial clinico sono molto promettenti, ma la loro applicabilità è limitata dal fatto che si riferiscono solo a lesioni coronariche focali ed isolate ed escludevano i pazienti con sindromi coronariche acute. Non sono ad oggi disponibili dati clinici sul comportamento di questo rivoluzionario stent nel trattamento di lesioni più complesse. Scopo - Il nostro obiettivo è di verificare se, in acuto, in un contesto anatomico e clinico più complesso di quello descritto finora in letteratura, lo scaffold possa essere sovrapponibile in sicurezza ed efficacia ai moderni stent medicati metallici. Per raggiungere questo scopo, ci siamo serviti della migliore tecnica di imaging attualmente disponibile per la diagnostica delle lesioni coronariche, la tomografia a coerenza ottica (OCT). Metodi - Nel corso del nostro studio sono stati arruolati tutti i pazienti consecutivi trattati con ABSORB dal Novembre 2012 a Agosto 2014, che presentavano almeno una delle seguenti caratteristiche: patologia multivasale e/o lesione lunga più di 20 mm. Sono stati inclusi anche i pazienti che presentavano infarto miocardico acuto con o senza sopraslivellamento del tratto ST. Una volta effettuata la coronarografia ed aver individuato le lesioni responsabili, il paziente veniva sottoposto ad angioplastica coronarica con l’impianto di almeno uno stent bioriassorbibile ABSORB. Abbiamo preferenzialmente utilizzato solo ABSORB per eseguire la rivascolarizzazione, impiantando stent metallici solo nel caso in cui non fossero stati disponibili ABSORB del diametro e lunghezza necessari. Durante la procedura è stata eseguita una valutazione diagnostica con OCT prima e subito dopo l’impianto di questo dispositivo. Risultati – Abbiamo arruolato 34 pazienti per un totale di 67 lesioni trattate con l’impianto di 81 ABSORB. Solo in un caso (1,2%) non è stato possibile impiantare lo scaffold per impossibilità di raggiungere la sede della lesione. Ciò non ha comunque inficiato il successo procedurale che è stato del 100%. In 49 lesioni su 67 (73,1%) è stato eseguito un esame OCT. In 18 lesioni l’esame non è stato eseguito per limitare la somministrazione di mezzo di contrasto iodato. Come conseguenza delle misurazioni OCT, in 12 casi su 49 (24,5%) è stata eseguita una post-dilatazione dell’ABSORB. L’espansione è apparsa ottimale nel 65,3% degli impianti. La presenza di sottoespansione dello stent è stata valutata mediante l’area luminale minima al termine della procedura, che è stata di 5,4±1,3 mm2, pari all’81±19% dell’area del vaso sano ai margini dello stent. Una sottoespansione focale o diffusa è stata visualizzata rispettivamente nel 18,4% e nel 16,3% dei casi. Nel 20,5% dei casi si è visualizzata una malapposizione focale dello stent, ovvero minore del 10% della sua lunghezza, senza casi di malapposizione diffusa. Ad un follow-up medio di 10 mesi, 2 pazienti su 34 (5,9%) hanno sviluppato ristenosi intra-stent sintomatica, trattata efficacemente con nuova rivascolarizzazione percutanea della lesione target. Trentadue pazienti su 34 (94,1%) sono rimasti asintomatici per angina durante il follow-up. Conclusioni – Il nostro studio ha dimostrato che lo stent ABSORB può essere impiantato con ottimo successo procedurale anche in lesioni coronariche lunghe e complesse ed in pazienti con coronaropatia multivasale. L’OCT intraprocedurale ha documentato una ottima apposizione degli ABSORB alla parete vasale, grazie anche all’accurato sizing dell’ABSORB mediante OCT pre-impianto; d’altro canto, l’OCT ha dimostrato che l’espansione è subottimale in una quota significativa di pazienti, nonostante la postdilatazione degli ABSORB. Questo dato appare tuttavia non significativamente diverso da quello riportato in letteratura riguardo ai DES in lesioni lunghe e complesse. Infine, i risultati clinici a breve termine indicano una sicurezza ed efficacia dell’ABSORB paragonabili a quelle degli stent medicati in questo gruppo di pazienti, con un basso tasso di nuova rivascolarizzazione delle lesioni trattate e con un’elevata libertà dal ritorno di angina

Seasonal variations in antioxidant components of cherry tomatoes (Lycopersicon esculentum cv. Naomi F1)

To evaluate seasonal variations in antioxidant components of greenhouse cherry tomatoes, the compositional profile of fruits ("Pomodoro di Pachino", cv. Naomi F1) harvested at six different times of the year was compared. Among tomato antioxidants, phenolic compounds (naringenin content ranged from 1.84 to 9.04 mg/100 g, rutin from 1.79 to 6.61 mg/100 g) and α-tocopherol (40-1160 μg/100 g) showed the greatest variability. Ascorbic acid (31-71 mg/100 g), carotenoids (8350-15119 μg/100 g), phenolics and α-tocopherol concentration did not show definite seasonal trends, nor correlation with solar radiation or average temperature. Nevertheless, tomatoes harvested in mid-summer were characterized by lowered lycopene levels. Greenhouse growing conditions induced the accumulation of relatively high level of antioxidants for most of the year: one serving of raw tomatoes (100 g) could provide from 50% to 120% of the recommended daily intake of vitamin C, from 13% to 27% of that of vitamin A, from 0.4% to 12% of that of vitamin E, and from 15% to 35% of the flavonoid daily intake estimated for an Italian diet

A Framework for Imbalanced Time-Series Forecasting

Time-series forecasting plays an important role in many domains. Boosted by the advances in Deep Learning algorithms, it has for instance been used to predict wind power for eolic energy production, stock market fluctuations, or motor overheating. In some of these tasks, we are interested in predicting accurately some particular moments which often are underrepresented in the dataset, resulting in a problem known as imbalanced regression. In the literature, while recognized as a challenging problem, limited attention has been devoted on how to handle the problem in a practical setting. In this paper, we put forward a general approach to analyze time-series forecasting problems focusing on those underrepresented moments to reduce imbalances. Our approach has been developed based on a case study in a large industrial company, which we use to exemplify the approach